Pirarubicin

Drug Profile

Pirarubicin

Alternative Names: 1609RB; Pinorubin; Tetrahydropyranyl doxorubicin; Theprubicina; Theprubicine; Therarubicin; THP

Latest Information Update: 16 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Almirall S.A.; CSL Behring; Meiji Seika Pharma; Mercian; Nippon Kayaku; Sanofi; sanofi-aventis
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Breast cancer; Cancer

Most Recent Events

  • 08 Jan 2007 ZLB Behring is now called CSL Behring
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 01 Apr 2004 Aventis Behring LLC has merged with ZLB Bioplasma to form ZLB Behring
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top